Search Results
Search for other papers by Roman A Romanov in
Google Scholar
PubMed
Department of Anatomy, Semmelweis University, Budapest, Hungary
Search for other papers by Alán Alpár in
Google Scholar
PubMed
Search for other papers by Tomas Hökfelt in
Google Scholar
PubMed
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Tibor Harkany in
Google Scholar
PubMed
contain all mRNAs for the protein domain sustaining the regulated release of any neurotransmitter or neuroactive modulator. Here, we will review recent data on corticotropin-releasing hormone (CRH) mRNA -containing neurons in the mammalian hypothalamus to
Department of Biological Chemistry, University of Michigan, 109 Zina Pitcher Place, BSRB Room 5035, Ann Arbor, Michigan 48109, USA
Search for other papers by Audrey F Seasholtz in
Google Scholar
PubMed
Search for other papers by Miina Öhman in
Google Scholar
PubMed
Search for other papers by Amale Wardani in
Google Scholar
PubMed
Department of Psychiatry, University of Michigan, 109 Zina Pitcher Place, BSRB Room 5035, Ann Arbor, Michigan 48109, USA
Search for other papers by Robert C Thompson in
Google Scholar
PubMed
Introduction Corticotropin-releasing hormone (CRH) is a key regulator of the endocrine, behavioral, and autonomic components of the mammalian stress response. Within the endocrine hypothalamic–pituitary–adrenal axis, this 41-amino acid peptide is
Search for other papers by Anne-Marie O'Carroll in
Google Scholar
PubMed
Search for other papers by Gillian M Howell in
Google Scholar
PubMed
Search for other papers by Emma M Roberts in
Google Scholar
PubMed
Search for other papers by Stephen J Lolait in
Google Scholar
PubMed
, Henquin 2000 ). The hypothalamic neuropeptide corticotropin-releasing hormone (CRH) plays a central role in the mammalian response to stress and exerts a wide range of roles in the brain (e.g., mediating anxiety behavior) and peripheral tissues (e
Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Neonatal Intensive Care Unit, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Search for other papers by V L Clifton in
Google Scholar
PubMed
Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Neonatal Intensive Care Unit, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Search for other papers by R Crompton in
Google Scholar
PubMed
Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Neonatal Intensive Care Unit, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Search for other papers by M A Read in
Google Scholar
PubMed
Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Neonatal Intensive Care Unit, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Search for other papers by P G Gibson in
Google Scholar
PubMed
Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Neonatal Intensive Care Unit, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Search for other papers by R Smith in
Google Scholar
PubMed
Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Neonatal Intensive Care Unit, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Search for other papers by I M R Wright in
Google Scholar
PubMed
Pathology 191 434 –442. Aguilera G , Nikodemova M, Wynn PC & Catt KJ 2004 Corticotropin releasing hormone receptors: two decades later. Peptides 25 319 –329. Algotsson A , Nordberg A
Department of Biological Pharmacy, School of Pharmacy, Shujitsu University, Okayama 703-8516, Japan
Search for other papers by Itsuo Murakami in
Google Scholar
PubMed
Department of Biological Pharmacy, School of Pharmacy, Shujitsu University, Okayama 703-8516, Japan
Search for other papers by Sakae Takeuchi in
Google Scholar
PubMed
Department of Biological Pharmacy, School of Pharmacy, Shujitsu University, Okayama 703-8516, Japan
Search for other papers by Toshiyuki Kudo in
Google Scholar
PubMed
Department of Biological Pharmacy, School of Pharmacy, Shujitsu University, Okayama 703-8516, Japan
Search for other papers by Shizuyo Sutou in
Google Scholar
PubMed
Department of Biological Pharmacy, School of Pharmacy, Shujitsu University, Okayama 703-8516, Japan
Search for other papers by Sumio Takahashi in
Google Scholar
PubMed
corticosterone levels ( Pulichino et al. 2003 b ). Hypothalamic corticotropin-releasing hormone (CRH) stimulates transcription of POMC and secretion of ACTH in vivo ( Bruhn et al. 1984 ), in cultured anterior pituitary cells ( Loeffler et al
Search for other papers by B Zbytek in
Google Scholar
PubMed
Search for other papers by LM Pfeffer in
Google Scholar
PubMed
Search for other papers by AT Slominski in
Google Scholar
PubMed
Corticotropin-releasing hormone (CRH) has been shown to inhibit proliferation and modulate expression of inflammation markers in the epidermal cells. In the present study we report that CRH also stimulates nuclear factor-kappa B (NF-kappaB) activity. Incubation with CRH of human keratinocytes derived from primary cultures resulted in increased binding of DNA by NF-kappaB. CRH induced translocation of NF-kappaB subunit p65 from the cytoplasm to the nucleus and induced expression of kappaB-driven chloramphenicol acetyltransferase (CAT) reporter gene. NF-kappaB translocation was accompanied by degradation of the inhibitor of NF-kappaB alpha (IkappaB-alpha). Specificity of the CRH effect was demonstrated by the use of CRH-R antagonists antalarmin and alpha-helical CRH [9-41]. CRH-dependent stimulation of NF-kappaB activity is consistent with accumulated data about role of this neuropeptide in the regulation of local epidermal homeostasis.
Search for other papers by AF Seasholtz in
Google Scholar
PubMed
Search for other papers by RA Valverde in
Google Scholar
PubMed
Search for other papers by RJ Denver in
Google Scholar
PubMed
Corticotropin-releasing hormone (CRH) plays multiple roles in vertebrate species. In mammals, it is the major hypothalamic releasing factor for pituitary adrenocorticotropin secretion, and is a neurotransmitter or neuromodulator at other sites in the central nervous system. In non-mammalian vertebrates, CRH not only acts as a neurotransmitter and hypophysiotropin, it also acts as a potent thyrotropin-releasing factor, allowing CRH to regulate both the adrenal and thyroid axes, especially in development. The recent discovery of a family of CRH-like peptides suggests that multiple CRH-like ligands may play important roles in these functions. The biological effects of CRH and the other CRH-like ligands are mediated and modulated not only by CRH receptors, but also via a highly conserved CRH-binding protein (CRH-BP). The CRH-BP has been identified not only in mammals, but also in non-mammalian vertebrates including fishes, amphibians, and birds, suggesting that it is a phylogenetically ancient protein with extensive structural and functional conservation. In this review, we discuss the biochemical properties of the characterized CRH-BPs and the functional roles of the CRH-BP. While much of the in vitro and in vivo data to date support an 'inhibitory' role for the CRH-BP in which it binds CRH and other CRH-like ligands and prevents the activation of CRH receptors, the possibility that the CRH-BP may also exhibit diverse extra- and intracellular roles in a cell-specific fashion and at specific times in development is also discussed.
Search for other papers by J Schulkin in
Google Scholar
PubMed
Glucocorticoids regulate corticotropin-releasing hormone (CRH) gene expression in the placenta and the brain. In both the placenta and two extrahypothalamic sites in the brain (the amygdala and the bed nucleus of the stria terminalis), glucocorticoids elevate CRH gene expression. One functional role of the elevation of CRH by glucocorticoids may be to signal adversity. When CRH is over-expressed in the placenta, it may indicate that the pregnancy is in danger, and preterm labor may result. When CRH is over-expressed in the brains of animals, they may become more fearful. Both situations possibly reflect allostatic mechanisms and vulnerability to allostatic overload, a condition in which biological tissue may be compromised.
Section of Endocrinology, Laboratorio in Rete del Tecnopolo Tecnologie delle Terapie Avanzate (LTTA), Division of Internal Medicine I, Department of Neurosurgery, Neurosurgery Unit, Department of Medical Sciences, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy
Search for other papers by Erica Gentilin in
Google Scholar
PubMed
Search for other papers by Federico Tagliati in
Google Scholar
PubMed
Search for other papers by Massimo Terzolo in
Google Scholar
PubMed
Search for other papers by Matteo Zoli in
Google Scholar
PubMed
Search for other papers by Marcello Lapparelli in
Google Scholar
PubMed
Search for other papers by Mariella Minoia in
Google Scholar
PubMed
Search for other papers by Maria Rosaria Ambrosio in
Google Scholar
PubMed
Section of Endocrinology, Laboratorio in Rete del Tecnopolo Tecnologie delle Terapie Avanzate (LTTA), Division of Internal Medicine I, Department of Neurosurgery, Neurosurgery Unit, Department of Medical Sciences, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy
Search for other papers by Ettore C degli Uberti in
Google Scholar
PubMed
Section of Endocrinology, Laboratorio in Rete del Tecnopolo Tecnologie delle Terapie Avanzate (LTTA), Division of Internal Medicine I, Department of Neurosurgery, Neurosurgery Unit, Department of Medical Sciences, University of Ferrara, Via Savonarola 9, 44100 Ferrara, Italy
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
replicates each and were expressed as the mean value± s.e.m. percent cell viability vs vehicle control cells. ** P <0.01 vs vehicle control cells. Time-course experiments showed that treatment with 100 nM corticotropin-releasing hormone (CRH
Search for other papers by F Mounier in
Google Scholar
PubMed
Search for other papers by E Pellegrini in
Google Scholar
PubMed
Search for other papers by C Kordon in
Google Scholar
PubMed
Search for other papers by J Epelbaum in
Google Scholar
PubMed
Search for other papers by M T Bluet-Pajot in
Google Scholar
PubMed
Involvement of endogenous corticotropin releasing hormone (CRH) in the regulation of spontaneous growth hormone (GH) secretion was investigated. A CRH antagonist, α helical CRH 9–41, was intracerebroventricularly infused for 36 h at a rate of 1 μg/0·5 μl/h to freely moving, cannulated adult male rats. Serial blood samples were drawn every 20 min for the last 8 hours of α helical CRH 9–41 infusion. The treatment induced a marked increase in GH peak amplitude without affecting either trough levels or numbers of peaks. In parallel, levels of growth hormone releasing hormone (GHRH) mRNA in the arcuate nucleus, but not of somatotropin release inhibiting hormone (SRIH) mRNA in the periventricular and arcuate nuclei, were increased. These data suggest that, in addition to its action in the stress-induced inhibition of GH secretion through regulation of periventricular SRIH neurons, CRH can also act as a modulator of endogenous GH secretion through regulation of arcuate GHRH neurons. Whether the modulatory effects of CRH on GHRH neurons are direct or indirect remains to be established.
Journal of Endocrinology (1997) 152, 431–436
